NEWARK, Calif., June 14, 2021 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage
biopharmaceutical company, today announced that it has commenced an
underwritten public offering of $100,000,000 of shares of its common stock. All
of the shares of common stock are being offered by Protagonist. In
connection with this offering, Protagonist expects to grant the
underwriters a 30-day option to purchase up to an additional 15% of
the number of shares of its common stock offered in the public
offering.
J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler are acting as joint book-running
managers for the offering. JMP Securities LLC and H.C. Wainwright
& Co., LLC are acting as co-lead managers for the offering. The
offering is subject to market conditions and there can be no
assurance as to whether or when the offering may be completed or
the actual size or terms of the offering.
A shelf registration statement relating to the offered shares of
common stock was filed with the Securities and Exchange Commission
(SEC) on December 10, 2020. A
preliminary prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and will be
available on the SEC's website, located at www.sec.gov. Prospective
investors should read the preliminary prospectus supplement, when
available, and the accompanying prospectus and other documents
Protagonist has filed with the SEC for more complete information
about Protagonist and the offering. Copies of the prospectus
supplement and the accompanying prospectus related to the offering
may be obtained, when available from J.P. Morgan Securities LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, by
telephone at 866-803-9204, or by email at
prospectus-eq_fi@jpmchase.com; Jefferies LLC (Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor,
New York, New York 10022;
telephone: 877-821-7388; email:
Prospectus_Department@Jefferies.com); or Piper Sandler & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800)
747-3924 or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms for
patients. Protagonist is headquartered in Newark, California.
Cautionary Note on Forward-Looking Statements
This
press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
regarding Protagonist's expectations regarding the completion,
timing and size of the proposed public offering. In some cases, you
can identify these statements by forward-looking words such as
"expect," "may," "will," or the negative or plural of these
words or similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances). These
forward-looking statements are based on Protagonist's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. These risks and uncertainties include, without
limitation, risks and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the
proposed public offering. There can be no assurance that
Protagonist will be able to complete the proposed public offering
on the anticipated terms, or at all. Additional information
concerning these and other risks can be found in Protagonist's
periodic filings with the SEC, including under the heading "Risk
Factors" contained therein, as well as the risks identified in the
registration statement and the preliminary prospectus supplement
relating to the offering. Any forward-looking statements that
Protagonist makes in this press release speak only as of the date
of this press release. Except as required by law, Protagonist
assumes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise,
after the date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-proposed-public-offering-of-common-stock-301311922.html
SOURCE Protagonist Therapeutics, Inc.